Peter Nolan Buys 249,687 Shares of Oxford BioMedica plc (LON:OXB) Stock
Oxford BioMedica plc (LON:OXB) insider Peter Nolan acquired 249,687 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were bought at an average price of GBX 8 ($0.10) per share, with a total value of £19,974.96 ($25,874.30).
Oxford BioMedica plc (LON:OXB) traded down 11.24% during mid-day trading on Monday, reaching GBX 7.50. 4,421,406 shares of the company’s stock were exchanged. The firm’s market cap is GBX 231.30 million. The stock has a 50-day moving average of GBX 5.36 and a 200-day moving average of GBX 4.70. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 11.25.
A number of research analysts have commented on OXB shares. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday. N+1 Singer reaffirmed a “hold” rating and set a GBX 7.80 ($0.10) price objective on shares of Oxford BioMedica plc in a report on Thursday, July 6th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a report on Thursday.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.